Surmodics raises FY23 EPS view to ($1.98)-($1.68) from ($2.09)-($1.69)

Consensus ($1.90). Raises FY23 revenue view to $103M-$106M from $102M-$106M, consensus $104.34M. Maharaj continued, "We are updating our guidance today to reflect our financial performance in the first half of fiscal 2023, as well as our revised expectations for the remainder of this year. In the second half of fiscal 2023, we remain focused on advancing the initial commercialization of our Sublime radial and Pounce arterial thrombectomy platforms, securing FDA approval for our SurVeil DCB, and driving revenue and cash flow from our Medical Device performance coating offerings and In Vitro Diagnostics business. We remain well-positioned from a liquidity perspective and committed to both prudent expense management and disciplined capital allocation as we pursue long-term revenue growth and value creation."